Novel Temperature-Sensitive Liposomes with Prolonged Circulation Time

Clinical Cancer Research

Volumn 10, Issue 6, 2004, Pages 2168-2178

  Lindner, Lars H ^a,b   Eichhorn, Martin E ^a   Eibl, Hansjoerg ^c   Teichert, Nicole ^a   Schmitt Sody, Marcus ^a   Issels, Rolf D ^a,b   Dellian, Marc ^a  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^b INSTITUTE OF EPIDEMIOLOGY   (Germany)

^c MAX PLANCK INSTITUTE FOR BIOPHYSICAL CHEMISTRY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

1,2 DIPALMITOYLGLYCERO 3 PHOSPHOGLYCEROGLYCEROL; DIPALMITOYLPHOSPHATIDYLCHOLINE; DIPALMITOYLPHOSPHATIDYLGLYCEROL; DISTEAROYLGLYCERO 3 PHOSPHOCHOLINE; LIPOSOME; PHOSPHOLIPID; UNCLASSIFIED DRUG;

AMELANOTIC MELANOMA; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AREA UNDER THE CURVE; ARTICLE; CANCER ADJUVANT THERAPY; CANCER PATIENT; CIRCULATION TIME; CONTROLLED STUDY; DRUG ACCUMULATION; DRUG EFFICACY; DRUG ELIMINATION; DRUG FORMULATION; DRUG HALF LIFE; DRUG RELEASE; ENCAPSULATION; FLUORESCENCE MICROSCOPY; HAMSTER; HYPERTHERMIA; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; TEMPERATURE SENSITIVITY;

1,2-DIPALMITOYLPHOSPHATIDYLCHOLINE; ANIMALS; CAPSULES; CRICETINAE; DRUG CARRIERS; HALF-LIFE; LIPOSOMES; MOLECULAR CONFORMATION; PHOSPHATIDYLCHOLINES;

EID: 1642392535     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-03-0035     Document Type: Article

References (57)

1. Needham D. Materials engineering of lipid bilayers for drug carrier function. MRS Bull 1999;24:32-40.
2. Cagnoni PJ. Liposomal amphotericin B versus conventional amphotericin B in the empirical treatment of persistently febrile neutropenic patients. J Antimicrob Chemother 2002;49:81-6.
3. Sparano JA, Winer EP. Liposomal anthracyclines for breast cancer. Semin Oncol 2001;28:32-40.
4. Muggia F, Hamilton A. Phase III data on Caelyx in ovarian cancer. Eur J Cancer 2001;37:S15-8.
5. Klibanov AL, Maruyama K, Torchilin VP, Huang L. Amphipathic polyethyleneglycols effectively prolong the circulation time of liposomes. FEBS Lett 1990;268:235-7.
6. Allen TM, Hansen C, Martin F, Redemann C, Yau-Young A. Liposomes containing synthetic lipid derivatives of poly(ethylene glycol) show prolonged circulation half-lives in vivo. Biochim Biophys Acta 1991;1066:29-36.
7. Blume G, Cevc G. Liposomes for the sustained drug release in vivo. Biochim Biophys Acta 1990;1029:91-7.
8. Judson I, Radford JA, Harris M, et al. Randomised phase II trial of pegylated liposomal doxorubicin (DOXIL/CAELYX) versus doxorubicin in the treatment of advanced or metastatic soft tissue sarcoma: a study by the EORTC Soft Tissue and Bone Sarcoma Group. Eur J Cancer 2001;37:870-7.
9. Issels RD. Hyperthermia and thermochemotherapy. Cancer Treat Res 1993;67:143-60.
10. Falk MH, Issels RD. Hyperthermia in oncology. Int J Hyperthermia 2001;17:1-18.
11. Wendtner CM, Abdel-Rahman S, Krych M, et al. Response to neoadjuvant chemotherapy combined with regional hyperthermia predicts long-term survival for adult patients with retroperitoneal and visceral high-risk soft tissue sarcomas. J Clin Oncol 2002;20: 3156-64.
12. Yatvin MB, Weinstein JN, Dennis WH, Blumenthal R. Design of liposomes for enhanced local release of drugs by hyperthermia. Science 1978;202:1290-3.
13. Gaber MH, Wu NZ, Hong K, Huang SK, Dewhirst MW, Papahadjopoulos D. Thermosensitive liposomes: extravasation and release of contents in tumor microvascular networks. Int J Radiat Oncol Biol Phys 1996;36:1177-87.
14. Needham D, Dewhirst MW. The development and testing of a new temperature-sensitive drug delivery system for the treatment of solid tumors. Adv Drug Deliv Rev 2001;53:285-305.
15. Kong G, Braun RD, Dewhirst MW. Characterization of the effect of hyperthermia on nanoparticle extravasation from tumor vasculature. Cancer Res 2001;61:3027-32.
16. Kong G, Braun RD, Dewhirst MW. Hyperthermia enables tumor-specific nanoparticle delivery: effect of particle size. Cancer Res 2000; 60:4440-5.
17. Gaber MH, Hong K, Huang SK, Papahadjopoulos D. Thermosensitive sterically stabilized liposomes: formulation and in vitro studies on mechanism of doxorubicin release by bovine serum and human plasma. Pharm Res 1995;12:1407-16.
18. Maruyama K, Unezaki S, Takahashi N, Iwatsuru M. Enhanced delivery of doxorubicin to tumor by long-circulating thermosensitive, liposomes and local hyperthermia. Biochim Biophys Acta 1993;1149: 209-16.
19. Papahadjopoulos D, Jacobson K, Nir S, Isac T. Phase transitions in phospholipid vesicles. Fluorescence polarization and permeability measurements concerning the effect of temperature and cholesterol. Biochim Biophys Acta 1973;311:330-48.
20. Kong G, Anyarambhatla G, Petros WP, et al. Efficacy of liposomes and hyperthermia in a human tumor xenograft model: importance of triggered drug release. Cancer Res 2000;60:6950-7.
21. Kong G, Dewhirst MW. Hyperthermia and liposomes. Int J Hyperthermia 1999;15:345-70.
22. Needham D, Anyarambhatla G, Kong G, Dewhirst MW. A new temperature-sensitive liposome for use with mild hyperthermia: characterization and testing in a human tumor xenograft model. Cancer Res 2000;60:1197-201.
23. Hildebrandt B, Wust P, Ahlers O, et al. The cellular and molecular basis of hyperthermia. Crit Rev Oncol Hematol 2002;43:33-56.
24. Anscher MS, Samulski TV, Dodge R, Prosnitz LR, Dewhirst MW. Combined external beam irradiation and external regional hyperthermia for locally advanced adenocarcinoma of the prostate. Int J Radiat Oncol Biol Phys 1997;37:1059-65.
25. Leopold KA, Oleson JR, Clarke-Pearson D, et al. Intraperitoneal cisplatin and regional hyperthermia for ovarian carcinoma. Int J Radiat Oncol Biol Phys 1993;27:1245-51.
26. Needham D, McIntosh TJ, Lasic DD. Repulsive interactions and mechanical stability of polymer-grafted lipid membranes. Biochim Biophys Acta 1992;1108:40-8.
27. Lopez AM, Wallace L, Dorr RT, Koff M, Hersh EM, Alberts DS. Topical DMSO treatment for pegylated liposomal doxorubicin-induced palmar-plantar erythrodysesthesia. Cancer Chemother Pharmacol 1999; 44:303-6.
28. Lyass O, Uziely B, Ben-Yosef R, et al. Correlation of toxicity with pharmacokinetics of pegylated liposomal doxorubicin (Doxil) in metastatic breast carcinoma. Cancer 2000;89:1037-47.
29. Alberts DS, Garcia DJ. Safety aspects of pegylated liposomal doxorubicin in patients with cancer. Drugs 1997;54:30-5.
30. Laverman P, Boerman OC, Oyen WJG, Corstens FHM, Storm G. In vivo applications of PEG liposomes: unexpected observations. Crit Rev Ther Drug Carrier Syst 2001;18:551-66.
31. Laverman P, Carstens MG, Boerman OC, et al. Factors affecting the accelerated blood clearance of polyethylene glycol-liposomes upon repeated injection. J Pharmacol Exp Ther 2001;298:607-12.
32. Eibl H. Synthesis of glycerophospholipids. Chem Phys Lipids 1980; 26:405-29.
33. Lasic DD. Preparation of liposomes. In: Lasic DD, editor. Liposomes from physics to applications. Amsterdam, the Netherlands: Elsevier Science; 1993. p. 63-107.
34. Eibl H, Lands WE. A new, sensitive determination of phosphate. Anal Biochem 1969;30:51-7.
35. United Kingdom Co-ordinating Committee on Cancer Research (UKCCCR) Guidelines for the Welfare of Animals in Experimental Neoplasia (second edition). Br J Cancer 1998;77:1-10.
36. Asaishi K, Endrich B, Gotz A, Messmer K. Quantitative analysis of microvascular structure and function in the amelanotic melanoma A-Mel-3. Cancer Res 1981;41:1898-904.
37. Heinzel G, Hammer R, Wolf M, Koss FW, Bozler G. [Model building in pharmacokinetics/part III: simplified rules for the deduction of analytical solutions for linear compartment models (author's transl)]. Arzneimittelforschung 1977;27:904-11.
38. Karino T, Koga S, Maeta M. Experimental studies of the effects of local hyperthermia on blood flow, oxygen pressure and pH in tumors. Jpn J Surg 1988;18:276-83.
39. Unezaki S, Maruyama K, Takahashi N, et al. Enhanced delivery and antitumor activity of doxorubicin using long-circulating thermosensitive liposomes containing amphipathic polyethylene glycol in combination with local hyperthermia. Pharm Res 1994;11:1180-5.
40. Iga K, Ohkouchi K, Ogawa Y, Toguchi H. Membrane modification by negatively charged stearyl-polyoxyethylene derivatives for thermosensitive liposomes: reduced liposomal aggregation and avoidance of reticuloendothelial system uptake. J Drug Target 1994;2:259-67.
41. Yuyama Y, Tsujimoto M, Fujimoto Y, Oku N. Potential usage of thermosensitive liposomes for site-specific delivery of cytokines. Cancer Lett 2000;155:71-7.
42. Gabizon A, Papahadjopoulos D. Liposome formulations with prolonged circulation time in blood and enhanced uptake by tumors. Proc Natl Acad Sci USA 1988;85:6949-53.
43. Gabizon A, Price DC, Huberty J, Bresalier RS, Papahadjopoulos D. Effect of liposome composition and other factors on the targeting of liposomes to experimental tumors: biodistribution and imaging studies. Cancer Res 1990;50:6371-8.
44. Papahadjopoulos D, Allen TM, Gabizon A, et al. Sterically stabilized liposomes: improvements in pharmacokinetics and antitumor therapeutic efficacy. Proc Natl Acad Sci USA 1991;88:11460-4.
45. Kakinuma K, Tanaka R, Takahashi H, Watanabe M, Nakagawa T, Kuroki M. Targeting chemotherapy for malignant brain tumor using thermosensitive liposome and localized hyperthermia. J Neurosurg 1996;84:180-4.
46. Matteucci ML, Anyarambhatla G, Rosner G, et al. Hyperthermia increases accumulation of technetium-99m-labeled liposomes in feline sarcomas. Clin Cancer Res 2000;6:3748-55.
47. Ishida O, Maruyama K, Yanagie H, Eriguchi M, Iwatsuru M. Targeting chemotherapy to solid tumors with long-circulating thermosensitive liposomes and local hyperthermia. Jpn J Cancer Res 2000;91: 118-26.
48. Lasic DD, Martin FJ, Gabizon A, Huang SK, Papahadjopoulos D. Sterically stabilized liposomes: a hypothesis on the molecular origin of the extended circulation times. Biochim Biophys Acta 1991;1070: 187-92.
49. Schagon O. Liposomen als potentielle Arzneistoffträger: Variation der biopharmazeutischen Eigenschaften durch 1,2-Dipalmitoyl-sn-glycero-3-phospho-oligo-glycerine. Braunschweig: Technische Universität; 1996.
50. Kao YJ, Loo TL. Pharmacological disposition of negatively charged phospholipid vesicles in rats. J Pharm Sci 1980;69:1338-40.
51. Kirby C, Clarke J, Gregoriadis G. Cholesterol content of small unilamellar liposomes controls phospholipid loss to high density lipoproteins in the presence of serum. FEBS Lett 1980;111:324-8.
52. Gregoriadis G, Senior J. The phospholipid component of small unilamellar liposomes controls the rate of clearance of entrapped solutes from the circulation. FEBS Lett 1980;119:43-6.
53. Senior J, Gregoriadis G. Is half-life of circulating liposomes determined by changes in their permeability? FEBS Lett 1982;145: 109-14.
54. Allen TM, Hansen C. Pharmacokinetics of stealth versus conventional liposomes: effect of dose. Biochim Biophys Acta 1991;1068:133-41.
55. Blume G, Cevc G. Molecular mechanism of the lipid vesicle longevity in vivo. Biochim Biophys Acta 1993;1146:157-68.
56. Unezaki S, Maruyama K, Ishida O, Takahashi N, Iwatsuru M. Enhanced tumor targeting of doxorubicin by ganglioside GM1-bearing long-circulating liposomes. J Drug Target 1993;1:287-92.
57. Arancia G, Calcabrini A, Matarrese P, Marcocci L, Pietrangeli P, Mondovi B. Effects of incubation with liposomes at different temperatures on cultured melanoma cells (M14). Int J Hyperthermia 1994;10: 101-14.